New Insights Into the Epidemiology of Bronchiectasis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed.

1. Systemic inflammation and oxidative stress in bronchiectasis-associated sarcopenia.ERJ open research · 2026
   Article
2. Respiratory symptoms associated with a new lobe-based bronchial scoring system in an urban Chinese low-dose CT screening population.European radiology · 2025
   Article
3. Aging Diminishes Mucociliary Clearance of the Lung.Advances in geriatric medicine and research · 2022
   Article
4. Survey of the management of patients with bronchiectasis: a pilot investigation in Asian populations.The Korean journal of internal medicine · 2021
   Article
5. Network Pharmacology Analysis of the Therapeutic Mechanisms Underlying Beimu-Gualou Formula Activity against Bronchiectasis withEvidence-based complementary and alternative medicine : eCAM · 2021
   Article
6. Imaging in non-cystic fibrosis bronchiectasis and current limitations.BJR open · 2021
   Review
7. The biology of pulmonary exacerbations in bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2019
   Review
8. Non-TB Mycobacterial Infection-Bronchiectasis Nexus.Chest · 2019
   Article
9. Real-world disease burden, mortality, and healthcare resource utilization associated with bronchiectasis.Chronic respiratory disease
   Article
10. Risk of Severe Bleeding With Extended Rivaroxaban to Prevent Venous Thromboembolism in Acute Medically Ill Patients With Bronchiectasis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Article

Corrections and comments

• Commented on by
  Non-TB Mycobacterial Infection-Bronchiectasis Nexus.2019
• Commented on by
  Response.2019
• Comment on
  Characteristics and Health-care Utilization History of Patients With Bronchiectasis in US Medicare Enrollees With Prescription Drug Plans, 2006 to 2014.2018

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as